- Home
- RGLS vs JVSA Comparison
RGLS vs JVSA Comparison
Compare RGLS & JVSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGLS
- JVSA
- Stock Information
- Founded
- RGLS 2007
- JVSA 2021
- Country
- RGLS United States
- JVSA Hong Kong
- Employees
- RGLS N/A
- JVSA N/A
- Industry
- RGLS Biotechnology: Pharmaceutical Preparations
- JVSA
- Sector
- RGLS Health Care
- JVSA
- Exchange
- RGLS Nasdaq
- JVSA NYSE
- Market Cap
- RGLS 74.0M
- JVSA 80.7M
- IPO Year
- RGLS 2012
- JVSA 2024
- Fundamental
- Price
- RGLS $1.31
- JVSA $10.68
- Analyst Decision
- RGLS Strong Buy
- JVSA
- Analyst Count
- RGLS 6
- JVSA 0
- Target Price
- RGLS $10.33
- JVSA N/A
- AVG Volume (30 Days)
- RGLS 820.1K
- JVSA 30.4K
- Earning Date
- RGLS 03-20-2025
- JVSA 01-01-0001
- Dividend Yield
- RGLS N/A
- JVSA N/A
- EPS Growth
- RGLS N/A
- JVSA N/A
- EPS
- RGLS N/A
- JVSA 0.24
- Revenue
- RGLS N/A
- JVSA N/A
- Revenue This Year
- RGLS N/A
- JVSA N/A
- Revenue Next Year
- RGLS N/A
- JVSA N/A
- P/E Ratio
- RGLS N/A
- JVSA $44.14
- Revenue Growth
- RGLS N/A
- JVSA N/A
- 52 Week Low
- RGLS $0.83
- JVSA $10.02
- 52 Week High
- RGLS $3.79
- JVSA $10.68
- Technical
- Relative Strength Index (RSI)
- RGLS 53.78
- JVSA N/A
- Support Level
- RGLS $1.22
- JVSA N/A
- Resistance Level
- RGLS $1.60
- JVSA N/A
- Average True Range (ATR)
- RGLS 0.13
- JVSA 0.00
- MACD
- RGLS 0.03
- JVSA 0.00
- Stochastic Oscillator
- RGLS 50.85
- JVSA 0.00
About RGLS Regulus Therapeutics Inc.
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.
About JVSA JVSPAC ACQUISITION CORP
JVSPAC Acquisition Corp is blank check company.